Skip to main content

Moleculin Biotech, Inc 8-K, filed Nov 4, 2026

Moleculin Biotech, Inc. (MBRX)

8-K 2026-11-04 For: 2026-11-04
View Original
Added on November 04, 2026

About this 8-K

Moleculin Biotech, Inc filed this 8-K on November 4, 2026.

Moleculin Biotech announced Annamycin data from the MB-108 Phase 2/3 trial for presentation at the 2026 American Society of Hematology (ASH) Annual Meeting; among 45 patients, complete remission was 43% and 36% in two treatment arms versus 12% in placebo. AI summary

Items reported

  • Item 7.01: Regulation FD disclosure
  • Item 9.01: Financial statements and exhibits